Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

Colorectal Cancer Clinical Trial

Official title:

Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00335595
• Other study ID #: TTD-05-02
• Secondary ID: EudraCT Nº: 2005
• Status: Completed
• Phase: Phase 3
• First received: June 9, 2006
• Last updated: February 19, 2013
• Start date: July 2006
• Est. completion date: June 2012

Study information

• Verified date: February 2013
• Source: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6 cycles followed by bevacizumab until disease progression or a premature drop out of the study.

Description:

The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6 cycles followed by bevacizumab until disease progression or a premature drop out of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 480
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent given.

• Patients who are able to understand the study request.

• Men and women > or = 18 years, not hospitalized.

• Outpatients with ECOG performance status = 2.

• Histologically confirmed diagnosis of colorectal cancer (CRC) patients with metastasis.

• Presence of at least one detectable lesion in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

• Life expectancy of greater than 3 months.

• Men and women potentially fertile using an effective contraceptive method

Exclusion Criteria:

• Patients who have been treated with bevacizumab previously.

• Received any systemic treatment previously to treat an advanced or metastatic disease

• Adjuvant or neoadjuvant treatment to non-metastatic disease is allowed, provided that it has been finished at least 6 months before the initial study treatment.

• If the patient has been treated with adjuvant therapy previously, it is not allowed to be included in the study in case of disease progression during treatment or for 6 months after the end of treatment.

• If radiotherapy has not been administered in the lesion selected for the study, previous radiotherapy is allowed, unless progression of those injuries can be documented in the radiated field, as long as the end of the treatment has been finished at least 4 weeks before study initiation.

• Previous surgical procedure of stage IV disease is allowed.

• Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or this study indication, unless there has been a disease-free interval of at least 2 years.

• History or evidence upon physical examination of central nervous system

• History of psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.

• Clinically significant cardiovascular disease (active).

• Patients who have undergone myocardial infarction or cerebrovascular accident 6 months prior to randomisation will be excluded.

• Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medications.

• Patients subjected to allogeneic transplant and request immunotherapy.

• Bone fracture not healed, wounds or severe ulcers.

• Known hemorrhagic diathesis or coagulopathy.

• Uncontrolled and severe intercurrent infections or other severe and uncontrolled concomitant diseases.

• Moderate or severe renal impairment (creatinine clearance < 30 ml/min [calculated according to Cockroft-Gault formula] or serum creatinine = 2 mg/dl or 177 µmol/l).

• Any of the following laboratory values:

• Absolute neutrophil count (ANC) = 1.5 x 10^9/l.

• Platelet count = 100 x 10^9/l.

• Hemoglobin = 9 g/dl.

• International Normalized Ratio (INR) = 1.5.

• Total bilirubin = 1.5 x upper limit of normal (ULN).

• ALT and/or AST = 2.5 x ULN or = 5 x ULN (in case of hepatic metastasis).

• Alkaline phosphatase > 2.5 x ULN or 5 x ULN (in case of hepatic metastasis), or > 10 x ULN (in case of bone metastasis).

• History of unexpected serious adverse events to fluoropyrimidine treatments or known dihydropyrimidine dehydrogenase (DPD) deficiency.

• Patients subjected to major surgical procedure or open biopsy; or patients have had significant traumatic injuries 28 days before the initial study treatment; or patients with a major surgical procedure planned during the study period.

• Fine needle aspiration biopsy 7 days before study initiation.

• Use of full dose of oral or parenteral anticoagulants (at least 10 days before the initial study treatment) or thrombolytic agents. Low dose of warfarin is allowed, with an INR = 1.5.

• Subjects requiring chronic use of high dose aspirin (> 325 mg/day) or non-steroidal anti-inflammatory treatment (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases).

• Pregnant or lactating women.

• Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies; or to any excipients of bevacizumab formulation; or to any other study drugs.

• Received any investigational drug or agent/procedure, i.e. participation in another treatment trial within 30 days of randomisation.

• Evidence of another disease, metabolic malfunction, discovery in a physical examination or in a clinical laboratory test to result in reasonable suspicion of a condition or disease that contraindicates investigational medicine use or exposes the patient to high risk treatment complications.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• XELOXA
XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
• XELOXA-A
XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study. One cycle every 3 weeks

Locations

Country	Name	City	State
Spain	Spanish Cooperative Group for Gastrointestinal Tumour Therapy	Madrid

Sponsors (3)

Lead Sponsor	Collaborator
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Roche Pharma AG, Sanofi

Country where clinical trial is conducted

Spain, 

References & Publications (4)

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lac — View Citation

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12. — View Citation

Díaz-Rubio E, Pietrantonio F, de Braud F. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17(11):1426-8. doi: 10.1634/theoncologist.2012-0075. Epub 2012 Oct 16. — View Citation

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the free time to disease progression		2006-2012	No
Secondary	Overall survival		2006-2012	No
Secondary	Overall response rate		2006-2012	No
Secondary	Time to onset of response		2006-2012	No
Secondary	Duration of response		2006-2012	No
Secondary	Treatment cycles number		2006-2012	No
Secondary	Number of patients who need medicine dose reduction		2006-2012	No
Secondary	adverse events		2006-2012	Yes
Secondary	Prognostic and predictive factor of Circulating endothelial cells (CEC) and circulating tumors cells (CTC) baseline and after 3 cycle		2006-2012	No
Secondary	Prognostic factor of the K-Ras gene mutation		2006-2012	No

External Links

•   Link